Skip to main content Skip to main navigation menu Skip to site footer

Survivin expression in ovarian carcinoma and its role as apoptotic inhibitor and prognostic predictor

  • I Gusti Ayu Sri Mahendra Dewi ,
  • Ni Putu Sriwidyani ,

Abstract

Background: Most ovarian cancers are diagnosed at advanced stages due to the lack of specific symptoms and lack of efficient screening methods. It is very important to examine prognostic predictor factors to increase survival rates. Survivin is a protein that plays a key role in inhibiting the process of programmed cell death or apoptosis, which will cause increased mitosis and cell proliferation as well as a worse prognosis. This study aims to prove the role of survivin as an inhibitor of apoptosis and predict prognosis by proving the existence of an association between survivin expression and mitotic index and proving the difference in survivin expression in type I and type II ovarian carcinoma.

Methods: A cross-sectional analytical observational study, a total sample of 40, taken from surgical specimens from ovarian carcinoma patients whose tissues were examined at the Anatomical Pathology Laboratory Faculty of Medicine Universitas Udayana/ Prof. dr. I G.N.G. Ngoerah Hospital Denpasar. Histopathological diagnosis and mitotic index were performed using H & E staining. Survivin expression was evaluated by immunohistochemical staining. Data analysis using chi-square test, significance value of p < 0.05.

Results: The mean age for type I ovarian carcinoma was 47.75 ± 11.50, and type II was 55.30 ± 6.11. The chi-square test shows a significant difference in survivin expression (p = 0.009) and in mitotic index (p = 0.001) of type I and type II ovarian carcinoma. A significant association was also found between survivin expression and mitotic index in type I (p = 0.046) and in type II ovarian carcinoma (p = 0.018).

Conclusion: There was a significant association between survivin expression and mitotic index and differences in survivin expression in type I and type II ovarian carcinoma.

Section

References

  1. Li XJ, Pang JS, Li YM, Ahmed FA, He RQ, Ma J, Ma FC, Chen G. Clinical value of survivin and its underlying mechanism in ovarian cancer: A bioinformatics study based on GEO and TCGA data mining. Pathology-Research and Practice. 2018;214(3);385-401.
  2. Raab M, Sanhaji M, Zhou S, Rodel F, El-Balat A, Becker S, Strebhardt K. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia. 2019;21(4);363-375.
  3. Bajger BG, Bodnar AG, Knapp P, Bodnar L. Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta-Analysis. J Clin Med. 2021;10(4):879.
  4. Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. PLOS One. 2018;3(1):e0191972.
  5. McCluggage WG, Lax SF, Longacre TA, Malpica A, Soslow RA. Tumours of the ovary: Introduction. In: WHO Classification of Tumours Editorial Board, editor. Female Genital Tumours. 5th Edition. Lyon: International Agency for Research on Cancer (IARC). 2020;1(1):31-163.
  6. Nan XW, Gong LH, Chen X, Zhou HH, Ye PP, Yang Y, et al. Survivin Promotes Piperlongumine Resistance in Ovarian Cancer. Front. Oncol; Sec. Molecular and Cellular Oncology. 2019;9(1):1345.
  7. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci. 2019;20(4):952.
  8. No HJ, Jeon YT, Kim YB, Song YS. Quantitative Detection of Serum Survivin and Its Relationship with Prognostic Factors in Ovarian Cancer. Gynecol Obstet Invest. 2011;7(1):136–140.
  9. Lu J, Tao X, Zhou J, Lu Y, Wang Z, Liu H, Xu C. Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis. Oncotarget. 2017;8(4):5843–5852.
  10. Longacre TA, Davidson B, Folkins AK, Kong CS, Malpica A, Vang R. Low-grade serous carcinoma of the ovary. In: WHO Classification of Tumours Editorial Board, editor. Female Genital Tumours. 5th Edition. Lyon: International Agency for Research on Cancer (IARC). 2020;1(1):43-47.
  11. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis. Mod Pathol. 2013;16(6):574–583.
  12. Babaier A, Mal H, Alselwi W, Ghatage P. Low-Grade Serous Carcinoma of the Ovary: The Current Status. Diagnostics. 2020;12(2):458.
  13. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
  14. He X, Yang K, Wang H, Chen X, Wu H, Yao L, et al. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis. 2018;13(5):e0194463.
  15. Berker B, Dunder I, Ensari A, Cengiz SD, Simsek E. Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur.J.Gynaec.Oncol. 2002;23(6):505-510
  16. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pacific journal of cancer prevention: APJCP. 2019;20(3):863.
  17. Prakosa T, Mudigdo A, Purwanto B, Wasita B, Cilmiaty R, Widianingsih V. A cross-sectional study: The correlation of pro-angiogenic factors expression level and epithelial ovarian cancer staging. Bali Medical Journal. 2020;9(1):125–128.
  18. Trirahmanto A, Haryana SM, Hakimi M, Pradjatmo H. The role of circulating MicroRNA-21 (miR-21) in epithelial ovarian cancer. Bali Medical Journal. 2019;8(1):128–133.
  19. Gafur A, Edianto D, Simanjuntak RY, Pasaribu HP, Ardiansyah E, Siregar HS. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) level difference in benign and malignant epithelial ovarian tumor. Bali Medical Journal. 2018;7(1):132–136.

How to Cite

Dewi, I. G. A. S. M., & Sriwidyani, N. P. (2024). Survivin expression in ovarian carcinoma and its role as apoptotic inhibitor and prognostic predictor . Indonesia Journal of Biomedical Science, 18(1), 70–76. https://doi.org/10.15562/ijbs.v18i1.532

HTML
22

Total
40

Share

Search Panel

I Gusti Ayu Sri Mahendra Dewi
Google Scholar
Pubmed
IJBS Journal


Ni Putu Sriwidyani
Google Scholar
Pubmed
IJBS Journal